{"groups":[{"description":"All patients randomized to the VTd group (Bortezomib (VELCADE), Thalidomide, and Dexamethasone) at rando 1 (even those who didn't receive any study treatment), not re-randomized in maintenance phase.","id":"FG000","title":"VTd Only"},{"description":"All patients randomized to the DVTd group (Daratumumab, Bortezomib (VELCADE), Thalidomide, and Dexamethasone) at rando 1 (even those who didn't receive any study treatment), not re-randomized in maintenance phase.","id":"FG001","title":"DVTd Only * Arm/Group Title: Characters Remaining: 91"},{"description":"All patients randomized to the VTd group (Bortezomib (VELCADE), Thalidomide, and Dexamethasone) at rando 1 (even those who didn't receive any study treatment), re-randomized to observation","id":"FG002","title":"VTd-OBS"},{"description":"All patients randomized to the VTd group (Bortezomib (VELCADE), Thalidomide, and Dexamethasone) at rando 1 (even those who didn't receive any study treatment), re-randomized to daratumumab monotherapy","id":"FG003","title":"VTd-DARA"},{"description":"All patients randomized to the DVTd group (Daratumumab, Bortezomib (VELCADE), Thalidomide, and Dexamethasone) at rando 1 (even those who didn't receive any study treatment), re-randomized to observation.","id":"FG004","title":"DVTd-OBS"},{"description":"All patients randomized to the DVTd group (Daratumumab, Bortezomib (VELCADE), Thalidomide, and Dexamethasone) at rando 1 (even those who didn't receive any study treatment), re-randomized to daratumumab monotherapy.","id":"FG005","title":"DVTd-DARA"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"50"},{"groupId":"FG001","numSubjects":"37"},{"groupId":"FG002","numSubjects":"48"},{"groupId":"FG003","numSubjects":"41"},{"groupId":"FG004","numSubjects":"21"},{"groupId":"FG005","numSubjects":"25"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}],"type":"Consent withdrawn"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}],"type":"Sponsor's decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"114"},{"groupId":"FG001","numSubjects":"85"},{"groupId":"FG002","numSubjects":"215"},{"groupId":"FG003","numSubjects":"213"},{"groupId":"FG004","numSubjects":"229"},{"groupId":"FG005","numSubjects":"229"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"53"},{"groupId":"FG001","numSubjects":"38"},{"groupId":"FG002","numSubjects":"165"},{"groupId":"FG003","numSubjects":"170"},{"groupId":"FG004","numSubjects":"205"},{"groupId":"FG005","numSubjects":"204"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"61"},{"groupId":"FG001","numSubjects":"47"},{"groupId":"FG002","numSubjects":"50"},{"groupId":"FG003","numSubjects":"43"},{"groupId":"FG004","numSubjects":"24"},{"groupId":"FG005","numSubjects":"25"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}